Swedish Orphan Biovitrum AB (publ)

SOBI.ST · Moat type: REGULIERUNG

MoatScore

8/10

Fair Value

945 SEK (≈ 98.21 USD)

Margin of Safety

+51.8 %

Rating

STARK

Swedish Orphan Biovitrum (SOBI) develops, manufactures and markets specialty pharmaceuticals for rare diseases, particularly in the areas of hemophilia, immunology and inflammatory diseases, and generates revenues primarily through patent-protected biologics with strong pricing power vis-à-vis government payers.

View full analysis →

🔒 Detailed AI analysis, peer comparison, capital allocation, crisis resilience & PDF report for Pro members.

Not investment advice. Analyses are research, not a recommendation. Valuations may be erroneous or incomplete. © MoatScan.ai — proprietary methodology.